Clinical trial · Observational
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
Single-center Real World Prospective Observational Study of Clinical Features, Treatment Patterns, and Survival of Bone and Soft Tissue Tumors
NCT05468970CI-TRIAL-00069268recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone and Soft Tissue Tumors | Soft Tissue Neoplasm | PROBABILISTIC | 0.70 |
| Clinical Features | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NO Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall survival
- timeFrame
- Up to approximately 120months
- description
- Pathologically confirmed events leading to death
- measure
- 6/5000 Progression-free survival
- timeFrame
- Up to approximately 48months
- description
- The time from the first use of the treatment to the observation of disease progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: All ages, male and female. The pathological diagnosis of BSTS in our hospital was a subtype. Has received at least one hospitalization in this hospital. The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes. Exclusion Criteria: No definite pathology.
References
Publications (0)
Data not yet available
No reference posted for this study.